0000950170-23-039165.txt : 20230807 0000950170-23-039165.hdr.sgml : 20230807 20230807171149 ACCESSION NUMBER: 0000950170-23-039165 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230804 FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burgess Paul D. CENTRAL INDEX KEY: 0001744627 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 231148465 MAIL ADDRESS: STREET 1: C/O TRANSLATE BIO, INC. STREET 2: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0508 4 2023-08-04 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001744627 Burgess Paul D. C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false See Remarks false Common Stock 2023-08-04 4 P false 21880 22.9339 A 21880 D The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Chief Business Development and Strategic Operations Officer /s/ Mark Bodenrader, as Attorney-in-Fact 2023-08-07